RASGRF1 Antibody

What is RASGRF1 and what are its primary functions in cellular signaling?

RASGRF1 is a guanine nucleotide exchange factor (GEF) similar to the Saccharomyces cerevisiae CDC25 gene product. It functions primarily by stimulating the dissociation of GDP from RAS protein, thereby facilitating RAS activation. RASGRF1 serves as an in vivo activator for H-RAS and members of the R-RAS and RAC subfamilies .

In the central nervous system (CNS), RASGRF1 is highly expressed at synaptic junctions and participates in regulating neurite outgrowth and neuronal excitability. Studies in mice have demonstrated that RASGRF1's Ras-GEF activity in the brain can be activated by Ca²⁺ influx, muscarinic receptors, and G protein beta-gamma subunits. These findings suggest that the Ras-GEF signaling pathway mediated by RASGRF1 plays a crucial role in long-term memory formation .

What are the structural domains of RASGRF1 that affect antibody selection?

RASGRF1 contains several functional domains that should be considered when selecting antibodies for specific research applications:

• REM-Cdc25 catalytic unit: Essential for guanine nucleotide exchange activity

• Diacylglycerol (DAG) binding domain: Facilitates membrane localization

• EF hand domains: Calcium-binding regions that regulate activity

• C-terminal tail: Influences plasma membrane recruitment

When selecting RASGRF1 antibodies, researchers should consider which domain is targeted by the antibody and whether post-translational modifications might affect epitope recognition. For instance, some antibodies specifically target the phosphorylated form at Ser916, which represents a functionally important regulatory site .

What species reactivity and tissue specificity should be considered when selecting RASGRF1 antibodies?

RASGRF1 antibodies show variable species reactivity that must be matched to experimental models:

RASGRF1 exhibits tissue-specific expression patterns, with highest expression in cerebellum, cerebral cortex, amygdala, and cells of the immune system. Certain antibodies have been specifically validated in brain tissue, demonstrating reliable detection in rat and mouse brain samples .

What are the recommended protocols for using RASGRF1 antibodies in Western blot applications?

For Western blot (WB) applications with RASGRF1 antibodies, follow these methodological guidelines:

• Sample preparation:

  • For brain tissue: Homogenize in RIPA buffer supplemented with phosphatase inhibitors and protease inhibitors

  • For cell lines: Perform cell lysis with RIPA buffer plus inhibitors

• Electrophoresis and transfer parameters:

  • Fractionate lysates by SDS-polyacrylamide gel electrophoresis

  • Transfer to nitrocellulose membranes (Trans-Blot Turbo transfer system works effectively)

• Antibody dilution ratios:

  • Primary antibody: 1:500-1:1000 for WB applications

  • Secondary antibody: Follow manufacturer's recommendations for HRP-conjugated antibodies

• Expected molecular weight:

  • Calculated molecular weight: 134 kDa

  • Observed molecular weight: 130-145 kDa (slight variations between antibodies)

• Signal development:

  • Use chemiluminescence with SuperSignal West Pico or Femto Chemiluminescent substrate

Note that RASGRF1 can undergo post-translational modification, including calpain-dependent cleavage that enhances its Ras-activating capacity, which may result in detection of truncated fragments .

How should RASGRF1 antibodies be optimized for immunohistochemistry and immunofluorescence studies?

For optimal immunohistochemistry (IHC) and immunofluorescence (IF) results:

• Tissue preparation:

  • Fix tissues appropriately (paraformaldehyde is commonly used)

  • For RASGRF1 in brain or synovial tissue, paraffin embedding works well

• Antigen retrieval methods:

  • Suggested antigen retrieval with TE buffer pH 9.0

  • Alternative: citrate buffer pH 6.0

• Recommended dilution ranges:

  • IHC: 1:50-1:500

  • IF: Follow specific antibody guidelines (typically similar to IHC range)

• Detection systems:

  • For double staining: Use appropriate secondary antibodies (e.g., goat anti-mouse HRP-conjugated or swine anti-rabbit-HRP-conjugated antibodies)

  • For fluorescence: FITC-conjugated secondary antibodies work well

• Counterstaining:

  • Mayer's hematoxylin is effective for IHC

  • For fluorescence microscopy, DAPI for nuclear counterstaining

Signal amplification with biotinylated tyramide and streptavidin-HRP has been successfully employed to enhance sensitivity in detecting RASGRF1 in tissue sections .

What controls should be included when using RASGRF1 antibodies in experimental procedures?

Robust experimental designs with RASGRF1 antibodies should include:

• Positive controls:

  • Rat brain tissue has been validated as a positive control for WB and IP

  • Mouse brain tissue works well for IHC applications

• Negative controls:

  • Omission of primary antibody

  • Irrelevant control antibodies of the same isotype

  • RASGRF1 knockdown or knockout samples (if available)

• Validation strategies:

  • Comparison with different antibodies targeting different epitopes

  • Correlation with mRNA expression data

  • Peptide competition assays

  • RASGRF1 silencing using locked nucleic acids (LNAs) as demonstrated in FLS cells

• Cross-reactivity assessment:

  • Test potential cross-reactivity with other RasGRF family members or related GEFs

  • Confirm specificity through Western blot or immunoprecipitation

How can RASGRF1 antibodies be used to investigate synovial tissue in rheumatoid arthritis research?

RASGRF1 has been implicated in rheumatoid arthritis (RA) pathogenesis, with enhanced expression in RA synovial tissue. Researchers can employ RASGRF1 antibodies to:

• Quantify differential expression:

  • Digital image analysis of immunohistochemical staining has revealed significantly higher RASGRF1 expression in RA synovial sublining compared to non-RA samples

  • Western blotting can detect post-translationally modified RASGRF1 in synovial biopsies

• Perform co-localization studies:

  • Double staining techniques using RASGRF1 antibodies alongside markers for:

    • T lymphocytes (anti-CD3)

    • Fibroblast-like synoviocytes (anti-CD55)

    • Macrophages (anti-CD68)

• Investigate functional outcomes:

  • RASGRF1 expression positively correlates with MMP-1 and MMP-3 production in RA synovial tissue

  • Cells expressing RASGRF1 can be analyzed for co-expression of inflammatory mediators

• Manipulate RASGRF1 expression:

  • RasGRF1 silencing using specific locked nucleic acids (LNAs) has been shown to inhibit spontaneous MMP-3 production in fibroblast-like synoviocytes

This research approach has demonstrated that RASGRF1 contributes to the semi-transformed phenotype of RA fibroblast-like synoviocytes and promotes matrix metalloproteinase production.

What role does RASGRF1 play in oncogenic signaling and how can antibodies help investigate this function?

RASGRF1 has recently been implicated in cancer development through several mechanisms that can be explored using antibody-based techniques:

• Detection of RASGRF1 fusions:

  • RASGRF1 fusions (such as OCLN-RASGRF1 and SLC4A4-RASGRF1) can activate oncogenic RAS signaling

  • These fusions can be detected using antibodies targeting the C-terminal portion of RASGRF1

• Analysis of RAS pathway activation:

  • RASGRF1 antibodies can help assess whether RASGRF1 overexpression correlates with increased GTP-RAS levels

  • Western blotting for phosphorylated downstream effectors (ERK1/2, JNK) can establish pathway activation

• Evaluation of cellular transformation:

  • Immunohistochemistry with RASGRF1 antibodies can identify expression patterns in tumor tissues

  • Correlation with markers of cellular transformation provides functional insights

• Investigation of gene silencing effects:

  • Following RASGRF1 knockdown, antibodies can confirm reduced protein expression

  • This approach has demonstrated that RASGRF1 silencing can reduce MMP production and potentially affect tumor invasiveness

Research has shown that RASGRF1 fusions increase cellular levels of active GTP-RAS, induce cellular transformation, and promote in vivo tumorigenesis, representing potential therapeutic targets .

How do post-translational modifications of RASGRF1 affect antibody recognition and protein function?

Post-translational modifications critically regulate RASGRF1 function and must be considered when selecting antibodies:

• Phosphorylation:

  • Phosphorylation at Ser916 represents a key regulatory modification

  • Phospho-specific antibodies (like ABIN7182582) enable specific detection of this activated form

  • This modification affects RASGRF1's nucleotide exchange activity

• Proteolytic cleavage:

  • Calpain-dependent cleavage generates truncated RASGRF1 fragments

  • In RA synovial tissue, RASGRF1 is detected as a truncated fragment lacking its negative regulatory domain

  • This modification enhances Ras-activating capacity both in vitro and in vivo

• Methodological considerations:

  • Use phosphatase inhibitors during sample preparation to preserve phosphorylation state

  • Consider using protease inhibitors to prevent artifactual cleavage during extraction

  • Select antibodies that recognize specific forms (full-length vs. cleaved) based on research question

The functional significance of these modifications can be studied using antibodies that distinguish between different RASGRF1 forms, providing insights into activation mechanisms in various disease states.

What are the optimal storage and handling conditions for RASGRF1 antibodies?

To maintain antibody integrity and performance, follow these storage and handling guidelines:

Prior to use:

• Centrifuge the vial before removing the cap to ensure maximum recovery

• Thaw completely but keep cold when in use

• Avoid repeated freeze-thaw cycles

• Some formulations contain BSA (0.1%) for stability

How can researchers validate the specificity of RASGRF1 antibodies for their particular experimental system?

To validate RASGRF1 antibody specificity in your experimental system:

• Multiple antibody approach:

  • Use antibodies targeting different epitopes of RASGRF1

  • Compare staining patterns and band sizes between antibodies

• Genetic manipulation controls:

  • RASGRF1 knockdown using siRNA or LNA technology

  • CRISPR/Cas9-mediated knockout cells or tissues

  • Overexpression systems with tagged RASGRF1

• Peptide competition assays:

  • Pre-incubate antibody with the immunizing peptide

  • Should abolish specific binding

• Cross-species validation:

  • Test reactivity across species if working with non-human models

  • Confirm antibody recognizes conserved epitopes

• Validation in multiple techniques:

  • Confirm consistent results across different applications (WB, IHC, IP)

  • Compare with published literature for expected expression patterns

The Research Resource Identifier (RRID) can help identify antibodies that have been previously validated (e.g., AB_2238126 or AB_2882327 for RASGRF1 antibodies) .

How should researchers address potential cross-reactivity with other Ras-GEF family members?

RASGRF1 belongs to a family of related guanine nucleotide exchange factors including RasGRP1-4 and other GEFs. To address potential cross-reactivity:

• Sequence alignment analysis:

  • Compare epitope sequences with other family members

  • Identify unique regions for specific recognition

• Expression system testing:

  • Test antibody against recombinant RasGRP1-4 or other RasGEFs

  • Confirm specificity for RASGRF1

• Cell type controls:

  • Use cell types with known expression profiles of different GEFs

  • RasGRP family members show distinct, sometimes overlapping distribution patterns in immune cells and brain regions

• Genetic verification:

  • Use knockout models of RASGRF1 alongside wild-type controls

  • This approach was successfully employed in studies examining ERK1/2 phosphorylation and FosB/ΔFosB immunoreactivity in RASGRF1 mutant mice

• Immunodepletion experiments:

  • Sequential immunoprecipitation with antibodies against different family members

  • Can help determine if signals are due to cross-reactivity

Understanding the specific structural domains targeted by your antibody will help predict and address potential cross-reactivity issues with related GEF family members.

How can RASGRF1 antibodies contribute to neurodegenerative disease research?

RASGRF1 antibodies offer valuable tools for investigating neurodegenerative mechanisms:

• Synaptic plasticity investigations:

  • RASGRF1 is highly expressed at synaptic junctions in the CNS

  • Antibodies can track expression changes during disease progression

  • Co-localization with synaptic markers can reveal functional relationships

• Long-term memory studies:

  • Mouse studies indicate RASGRF1's importance for long-term memory

  • Antibodies can help correlate protein levels with memory deficits

  • Phospho-specific antibodies can track activation state changes

• L-DOPA-induced dyskinesia research:

  • Ras-GRF1 ablation reduces abnormal involuntary movements (AIMs) in mouse models

  • Antibodies against RASGRF1 and downstream effectors (phospho-ERK1/2, FosB/ΔFosB) help elucidate mechanisms

  • Immunoreactivity patterns provide insights into therapeutic interventions

• Methodological approach:

  • Immunohistochemistry in brain regions affected by neurodegeneration

  • Western blotting to quantify expression level changes

  • Co-immunoprecipitation to identify disease-specific interaction partners

By tracking RASGRF1 expression and activation in neurodegenerative contexts, researchers can better understand disease mechanisms and identify potential therapeutic targets.

What methodologies can be used to investigate RASGRF1's role in T cell receptor signaling pathways?

Investigating RASGRF1's function in T cell receptor (TCR) signaling requires specialized approaches:

• Expression analysis in immune cell subtypes:

  • Western blotting or flow cytometry with RASGRF1 antibodies

  • RasGRP1 is highly expressed in mature and developing T cells

• Membrane recruitment visualization:

  • Immunofluorescence microscopy to track RASGRF1 localization following TCR stimulation

  • Co-localization with TCR components and signaling molecules

• Activation state monitoring:

  • Phospho-specific antibodies to monitor RASGRF1 activation

  • Correlation with downstream signaling (Ras-GTP levels, ERK phosphorylation)

• Functional manipulation:

  • RASGRF1 silencing using LNAs followed by assessment of:

    • ERK1/2 activation

    • IL-6 and IL-8 production

    • Cell proliferation responses

• Methodological considerations:

  • Co-immunoprecipitation to identify TCR-associated complexes

  • ELISA to quantify cytokine production following manipulation

  • RasGTP pull-down assays to directly measure Ras activation

This research approach has revealed that RasGRP proteins function as non-redundant TCR-coupled GEFs, distinct from SOS GEFs, providing insights into T cell development and function .

How should researchers approach epitope mapping and antibody validation for RASGRF1 fusion proteins in cancer research?

When investigating RASGRF1 fusion proteins in cancer contexts:

• Fusion protein characteristics:

  • OCLN-RASGRF1 and SLC4A4-RASGRF1 fusions retain RASGRF1's catalytic domains

  • These fusions increase cellular levels of active GTP-RAS

  • They induce cellular transformation and promote tumorigenesis

• Epitope mapping strategies:

  • Select antibodies targeting regions preserved in fusion proteins

  • Use multiple antibodies targeting different domains to confirm fusion structure

  • Consider developing fusion-specific antibodies that target junction regions

• Experimental validation approach:

  • Express recombinant fusion proteins as positive controls

  • Use PCR to verify fusion transcript presence alongside antibody detection

  • Perform immunoprecipitation followed by mass spectrometry for definitive identification

• Functional assessment:

  • Correlate antibody detection with RAS pathway activation markers

  • Monitor transformation phenotypes in positive cells

  • Track tumor formation in xenograft models

• Technical considerations:

  • Western blotting may reveal bands of unexpected sizes due to fusion

  • Immunohistochemistry patterns may differ from wild-type RASGRF1

  • Controls should include both wild-type RASGRF1 and fusion-negative samples

This comprehensive approach enables researchers to effectively characterize RASGRF1 fusion events and their contribution to oncogenic mechanisms, potentially identifying new therapeutic targets .